PDGFRA and scleroderma: An agonistic anti-PDGFRα monoclonal antibody, but not the non-agonistic one, induced enhanced collagen deposition, increased fibroblast activation markers, and vascular alterations in the dermis of human skin equivalents, leading to scleroderma-like skin fibrosis.